A Phase 3 interventional study of Eflornithine and Eflornithine Placebo in Familial Adenomatous Polyposis, sponsored by Cancer Prevention Pharmaceuticals, Inc.. Completed at 17 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-08.
Sponsored by Cancer Prevention Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Adenomatous Polyposis Coli with a site in United States — 12 open to participants now, 12 under way, 1 of them phase 3. Adenomatous Polyposis Coli · United States.
Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, this one is the 4th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 14th registered.
92 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.
Browse Adenomatous Polyposis Coli studies →12 of the 39 studies in Adenomatous Polyposis Coli with a site in United States are open now. Recruiting first, the newest first:
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
HonorHealth Research Institute · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Rapamycin Holdings Inc. · Sites in United States, Denmark, Germany and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Adenomatous Polyposis Coli studies recruiting now, 15 (75%) set no upper age limit and 2 (10%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 3
First in 2001; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 171 is above the median of 40 across 61 interventional studies indexed under Adenomatous Polyposis Coli.
Median enrollment 42 across the 27 interventional studies, 833 across the 12 observational. Of the 26 that completed or were terminated, 13 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 39 have an industry lead sponsor. The 10 most frequent:
Cancer Prevention Pharmaceuticals, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Cancer Prevention Pharmaceuticals, Inc. has 2 studies filed under Adenomatous Polyposis Coli — fewer than ten, so there is no comparison to draw.
6 of the studies in Adenomatous Polyposis Coli with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04678011Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy | 2026-11 |
| NCT04677998Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis | 2026-11 |
| NCT05919264Parabilis Medicines, Inc.FOG-001 in Locally Advanced or Metastatic Solid Tumors | 2027-04-01 |
| NCT05552755Recursion Pharmaceuticals Inc.Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | 2027-06 |
| NCT06557733National Cancer Institute (NCI)An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized, double-blind, Phase III trial is to determine if the combination of eflornithine plus sulindac is superior to sulindac or eflornithine as single agents in delaying time to the first occurrence of any FAP-related event. This includes: 1) FAP related disease progression indicating the need for excisional intervention involving the colon, rectum, pouch, duodenum and/or 2) clinically important events which includes progression to more advanced duodenal polyposis, cancer or death.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of phenotypic classical FAP with disease involvement of the duodenum and/or colon/rectum/pouch.
Rectal/pouch polyposis as a stratification site as follows:
At least three years since colectomy with ileorectal anastamosis (IRA)/proctocolectomy with pouch, and demonstrating polyposis as defined by Stage 1, 2, 3, of the proposed InSiGHT 2011 Staging System (Appendix B) and summarized as follows:
Stage 1: 10-25 polyps, all \< 5 mm Stage 2: 10-25 polyps, at least one > 1 cm Stage 3: >25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any evidence of high grade dysplasia, even if completely removed. [Note: For staging purposes only.]
Duodenal polyposis as a stratification site; one or more of the following:
Hematopoietic Status (within 30 days prior to randomization):
Hepatic Status (within 30 days prior to randomization):
Renal Status (within 30 days prior to randomization):
a) Creatinine no greater than 1.5 times ULN
Hearing:
a) No hearing loss, defined in Section 6.2, number 9.
Exclusion Criteria:
Patients must not have cardiovascular disease risk factors as defined below:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eflornithine 750 mg and Sulindac 150 mg
Drug: Eflornithine · Drug: Sulindac 150 MG
Eflornithine 750 mg and Placebo
Drug: Eflornithine · Drug: Sulindac placebo
Sulindac 150 mg and Placebo
Drug: Eflornithine Placebo · Drug: Sulindac 150 MG
Eflornithine \[250 mg tablet, three tablets (750 mg) orally once a day\]
Also known as: CPP-1X
Eflornithine placebo \[three tablets orally once a day\]
Also known as: CPP-1X placebo
Sulindac \[one tablet orally once a day\]
Also known as: Clinoril
Sulindac placebo \[one tablet orally once a day\]
Number of Subjects With Any FAP-related Event.
Progression of disease by evaluation of FAP-related events over the course of study treatment
Time frame: Up to 48 months from the start of treatment
Improvement in Investigator Upper GI Assessment
Global assessment of change in upper GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint.
Time frame: through month 12 assessment
Improvement in Investigator Lower GI Assessment
Global assessment of change in lower GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint.
Time frame: through month 12 assessment
| Milestone | Eflornithine Plus Sulindac | Eflornithine Plus Sulindac Placebo | Sulindac Plus Eflornithine Placebo |
|---|---|---|---|
| Started | 56 | 57 | 58 |
| Completed | 41 | 44 | 43 |
| Not completed | 15 | 13 | 15 |
| Withdrew: Adverse event | 9 | 4 | 6 |
| Withdrew: Withdrawal by subject | 0 | 2 | 5 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 4 | 1 |
| Withdrew: Protocol violation | 3 | 3 | 3 |
Progression of disease by evaluation of FAP-related events over the course of study treatment
| Participants | Eflornithine Plus Sulindac | Eflornithine Plus Sulindac Placebo | Sulindac Plus Eflornithine Placebo |
|---|---|---|---|
| Number with FAP-related events | 18 | 23 | 22 |
| Number with Lower GI FAP-related events | 2 | 10 | 9 |
Global assessment of change in upper GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint.
| Participants | Eflornithine Plus Sulindac | Eflornithine Plus Sulindac Placebo | Sulindac Plus Eflornithine Placebo |
|---|---|---|---|
| Improved | 11 | 10 | 10 |
| Not Improved | 45 | 47 | 48 |
Global assessment of change in lower GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint.
| Participants | Eflornithine Plus Sulindac | Eflornithine Plus Sulindac Placebo | Sulindac Plus Eflornithine Placebo |
|---|---|---|---|
| Improved | 22 | 16 | 22 |
| Not Improved | 34 | 41 | 36 |
Collected over Up to 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eflornithine Plus Sulindac | 0/56 (0%) | 11/56 (19.6%) | 52/56 (92.9%) |
| Eflornithine Plus Sulindac Placebo | 0/56 (0%) | 14/56 (25%) | 49/56 (87.5%) |
| Sulindac Plus Eflornithine Placebo | 0/57 (0%) | 11/57 (19.3%) | 50/57 (87.7%) |
| Event | Eflornithine Plus Sulindac | Eflornithine Plus Sulindac Placebo | Sulindac Plus Eflornithine Placebo |
|---|---|---|---|
| small intestinal obstructionGastrointestinal disorders | 2/56 | 1/56 | 2/57 |
| abdominal painGastrointestinal disorders | 1/56 | 0/56 | 1/57 |
| ileusGastrointestinal disorders | 1/56 | 1/56 | 0/57 |
| constipationGastrointestinal disorders | 0/56 | 1/56 | 0/57 |
| inguinal herniaGastrointestinal disorders | 1/56 | 0/56 | 0/57 |
| pancreatitisGastrointestinal disorders | 0/56 | 1/56 | 0/57 |
| pancreatitis acuteGastrointestinal disorders | 1/56 | 0/56 | 0/57 |
| biliary colicHepatobiliary disorders | 0/56 | 1/56 | 0/57 |
| alcohol poisoningInjury, poisoning and procedural complications | 0/56 | 1/56 | 0/57 |
| post procedural hemorrhageInjury, poisoning and procedural complications | 0/56 | 1/56 | 0/57 |
| Event | Eflornithine Plus Sulindac | Eflornithine Plus Sulindac Placebo | Sulindac Plus Eflornithine Placebo |
|---|---|---|---|
| nauseaGastrointestinal disorders | 12/56 | 9/56 | 12/57 |
| headacheNervous system disorders | 8/56 | 5/56 | 11/57 |
| nasopharyngitisInfections and infestations | 6/56 | 10/56 | 4/57 |
| vomitingGastrointestinal disorders | 6/56 | 7/56 | 10/57 |
| diarrhoeaGastrointestinal disorders | 7/56 | 8/56 | 6/57 |
| abdominal painGastrointestinal disorders | 8/56 | 4/56 | 8/57 |
| fatigueGeneral disorders | 4/56 | 8/56 | 8/57 |
| upper respiratory tract infectionInfections and infestations | 8/56 | 2/56 | 8/57 |
| abdominal pain upperGastrointestinal disorders | 7/56 | 4/56 | 1/57 |
| rectal haemorrhageGastrointestinal disorders | 7/56 | 4/56 | 7/57 |
| Age, Continuous(years) | Eflornithine Plus Sulindac | Eflornithine Plus Sulindac Placebo | Sulindac Plus Eflornithine Placebo | Total |
|---|---|---|---|---|
| Mean | 37.8 ± 13.35 | 39.7 ± 14.76 | 38.1 ± 13.66 | 38.5 ± 13.88 |
| Sex: Female, Male(Participants) | Eflornithine Plus Sulindac | Eflornithine Plus Sulindac Placebo | Sulindac Plus Eflornithine Placebo | Total |
|---|---|---|---|---|
| Female | 22 | 29 | 21 | 72 |
| Male | 34 | 28 | 37 | 99 |
| Ethnicity (NIH/OMB)(Participants) | Eflornithine Plus Sulindac | Eflornithine Plus Sulindac Placebo | Sulindac Plus Eflornithine Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 5 | 3 | 13 |
| Not Hispanic or Latino | 50 | 50 | 54 | 154 |
| Unknown or Not Reported | 1 | 2 | 1 | 4 |
| Race (NIH/OMB)(Participants) | Eflornithine Plus Sulindac | Eflornithine Plus Sulindac Placebo | Sulindac Plus Eflornithine Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 1 | 3 | 10 |
| White | 48 | 54 | 50 | 152 |
| More than one race | 0 | 0 | 2 | 2 |
| Unknown or Not Reported | 2 | 2 | 2 | 6 |
| Region of Enrollment(participants) | Eflornithine Plus Sulindac | Eflornithine Plus Sulindac Placebo | Sulindac Plus Eflornithine Placebo | Total |
|---|---|---|---|---|
| Canada | 6 | 6 | 4 | 16 |
| Netherlands | 4 | 6 | 5 | 15 |
| Belgium | 1 | 3 | 0 | 4 |
| United States | 31 | 30 | 42 | 103 |
| United Kingdom | 3 | 3 | 2 | 8 |
| Germany | 9 | 6 | 4 | 19 |
| Spain | 2 | 3 | 1 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Oct 2013, a primary completion of Nov 2018 and a completion of Mar 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2021, 2 years 7 months after primary completion. A results delay was requested in Jan 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Eflornithine · Sulindac
Cancer Prevention Pharmaceuticals, Inc.